Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) registered a 4.80% increase, still its new closing price is 105.03% up from the company’s 1 year high of 16.89.It posted 4.80% gains in previous 5 sessions and is now the subject of 6 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 1 sells versus 2 buy or better ratings. The 12 stock analysts following this company have an average price target at $15.79, with individual PT in the $8.00-$21.00 range. The shares moved at $15.07, implying that brokerage firms see shares gaining about 70.09% in twelve months time.
Ironwood Pharmaceuticals, Inc. (IRWD) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a -1.44% fall year to date. A CEO at Ironwood Pharmaceuticals, Inc. (IRWD) offloaded shares in a transaction closed on Thursday January 12, 2017. Hecht Peter M sold 65,987 shares in the company at $15.67 each and collected $1,034,000 in proceeds. Hecht Peter M now owns 4,684,872 shares in the company after this transaction. A Director in the company, OLANOFF LAWRENCE S, disclosed a transaction on Monday December 05, 2016 that ended up generating $50,000 from the sale of 3,200 shares at $15.68 per share.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Upcoming Results on Tap
Ironwood Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.05 in that period. Sales during the quarter are predicted to arrive at $75.37 million.
Earnings surprise history: Last quarter, the company posted approximately $66.11 million in revenue and EPS of $-0.23. The mean forecast was for $60.01 million and $-0.23 a share, respectively. One quarter earlier, revenue for the stock was at $54.35 million, with earnings at $-0.14/share.
Ironwood Pharmaceuticals, Inc. (IRWD) Brokerage Update
Ironwood Pharmaceuticals, Inc. (IRWD) is in Cantor Fitzgerald’s research list so their analyst rating change is noteworthy. These shares were upgraded to Hold from Sell by Cantor Fitzgerald, according to news reported on Wednesday July 24, 2013.Another important research note was issued by UBS on Wednesday January 16, 2013.The firm downgraded IRWD to Sell from Neutral. Over the last six months and over the last three months, the shares of Ironwood Pharmaceuticals, Inc. (IRWD), have changed 8.97% and 18.01%, respectively.